| Identification | Back Directory | [Name]
SW-100 | [CAS]
2126744-35-0 | [Synonyms]
SW-100
HDAC,SW-100,Histone deacetylases,Inhibitor,SW 100,inhibit,SW100
4-((6-CHLORO-3,4-DIHYDROQUINOLIN-1(2H)-YL)METHYL)-N-HYDROXYBENZAMIDE
Benzamide, 4-[(6-chloro-3,4-dihydro-1(2H)-quinolinyl)methyl]-N-hydroxy- | [Molecular Formula]
C17H17ClN2O2 | [MDL Number]
MFCD32067911 | [MOL File]
2126744-35-0.mol | [Molecular Weight]
316.78 |
| Hazard Information | Back Directory | [Uses]
SW-100 HDAC6 Inhibitor is used in methods of treating PACS1 and PACS2 syndromes comprising administering an HDAC6 or SIRT2 inhibitor in relation to restoring Golgi morphology in a cell. | [in vivo]
SW-100 (20 mg/kg; i.p.; twice a day for two days) ameliorates several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in mouse model of Fragile X syndrome[1]. | Animal Model: | 8-10 weeks old C57BL/6 mice (Fmr1-/- mice)[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; twice a day for two days | | Result: | Ameliorated several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in Fmr1-/- mice。 |
| [IC 50]
HDAC1: 5.23 μM (IC50); HDAC2: 32.8 μM (IC50); HDAC3: 29.5 μM (IC50); HDAC4: 10.9 μM (IC50); HDAC5: 4.07 μM (IC50); HDAC6: 2.3 nM (IC50); HDAC7: 4.55 μM (IC50); HDAC8: 3.72 μM (IC50); HDAC9: 3.46 μM (IC50); HDAC10: 26.2 μM (IC50); HDAC11: 5.72 μM (IC50) |
|
|